A detailed history of Pro Share Advisors LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 16,664 shares of ETNB stock, worth $120,647. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,664
Previous 20,737 19.64%
Holding current value
$120,647
Previous $241,000 44.81%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$7.31 - $10.9 $29,773 - $44,395
-4,073 Reduced 19.64%
16,664 $133,000
Q1 2024

May 08, 2024

BUY
$8.13 - $13.77 $43,243 - $73,242
5,319 Added 34.5%
20,737 $241,000
Q4 2023

Feb 14, 2024

BUY
$6.66 - $16.03 $16,310 - $39,257
2,449 Added 18.88%
15,418 $172,000
Q3 2023

Nov 13, 2023

BUY
$15.06 - $19.41 $3,222 - $4,153
214 Added 1.68%
12,969 $200,000
Q2 2023

Aug 10, 2023

BUY
$14.15 - $22.03 $180,483 - $280,992
12,755 New
12,755 $241,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $337M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.